Bio-Rad Laboratories Inc. is facing mixed results presently in the market. While there have been some losses and a perceived disappointing outcome, the company's stock has faced increases in periods as well, such as a 3.06% rise on March 17. Several major investors such as
Gotham Asset Management and
Moore Capital Management have made substantial acquisitions in the company, indicating their faith in its potential recovery. Analysts have put the company under scrutiny based on various factors including the effect of NIH budget cuts. Meanwhile, brokerage consensus suggests a 'Hold' rating due to the share price softness and mixed performance of late. Investment firms such as
Capital Research Global Investors and
Mangrove Partners IM have made new investments, while others such as
Fisher Asset Management have reduced their stock positions. Q3 earnings have missed estimates, causing stock to fall. The firm's core growth is deemed underwhelming, despite experiencing modest revenue growth. Diagnostics rebound sees BIO returning to profitability, but macroeconomic instability and limited growth potential cause investor's pause.
Bio-Rad Laboratories Stocks News Analytics from Wed, 02 Dec 2020 21:42:53 GMT to Fri, 20 Mar 2026 13:57:15 GMT -
Rating 1
- Innovation -3
- Information 5
- Rumor -5
